Skip to Main Content
Close
Who We Serve
Overview
Researchers
Authors
Reviewers
Healthcare Professionals
Patients & Supporters
Librarians
Health Sciences Industry
Medical Societies
Agents & Distributors
What We Offer
Overview
Journals
Collections
Subject Areas
Books & Book Series
E-Learning Courses
Healthcare Podcasts
Open Access Portfolio
Communications & Outreach
Who We Are
Overview
What We Solve
Accessing Knowledge
Presenting Knowledge
Applying Knowledge
About Us
Publish with Us
Overview
Publish Your Paper
Calls for Papers
Publication Services
Partner Publications
Submit & Publish Open Access
Resources for You
Overview
Exhibitions
Webinars
Case Studies
News & Media Releases
Fast Facts Info Series
Experience Karger Blog
The Waiting Room Blog
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
All Journals
Acta Haematologica
Search
Advanced Search
User Tools Dropdown
Register
Login
Toggle Menu
Menu
Content
Articles
Issues
Online First
Early View
About
Details
Contact
Editorial Board
Guidelines
Subscription Rates
Rights & Permissions
Advertising
Submission
Skip Nav Destination
Acknowledgements
Acta Haematol
(1995) 94 (4): 219–220.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
Raoul Tibes
Ruben Mesa
Clinical Investigation
(2011) 1 (12): 1681.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
